2.38
-0.08(-3.25%)
Currency In USD
| Previous Close | 2.46 |
| Open | 2.4 |
| Day High | 2.42 |
| Day Low | 2.34 |
| 52-Week High | 36 |
| 52-Week Low | 1.41 |
| Volume | 9,801 |
| Average Volume | 1.69M |
| Market Cap | 3.51M |
| PE | -0.11 |
| EPS | -21.94 |
| Moving Average 50 Days | 2.47 |
| Moving Average 200 Days | 3.89 |
| Change | -0.08 |
If you invested $1000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) since IPO date, it would be worth $8.48 as of July 06, 2025 at a share price of $2.38. Whereas If you bought $1000 worth of 60 Degrees Pharmaceuticals, Inc. (SXTP) shares 1 year ago, it would be worth $171.59 as of July 06, 2025 at a share price of $2.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
GlobeNewswire Inc.
Jun 04, 2025 12:56 PM GMT
New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmace
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
GlobeNewswire Inc.
Jun 03, 2025 12:49 PM GMT
25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis cases include chronic fatigueHealthcare providers treating patients who present with unex
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
GlobeNewswire Inc.
May 15, 2025 8:31 PM GMT
Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharm